Immune checkpoint-related serum proteins and genetic variants predict outcomes of localized prostate cancer, a cohort st
- PDF / 2,108,078 Bytes
- 12 Pages / 595.276 x 790.866 pts Page_size
- 69 Downloads / 171 Views
ORIGINAL ARTICLE
Immune checkpoint‑related serum proteins and genetic variants predict outcomes of localized prostate cancer, a cohort study Qinchuan Wang1 · Yuanqing Ye2 · Hao Yu3 · Shu‑Hong Lin4 · Huakang Tu3 · Dong Liang5 · David W. Chang3 · Maosheng Huang3 · Xifeng Wu2 Received: 24 May 2020 / Accepted: 1 September 2020 © The Author(s) 2020
Abstract Background The clinical predictors and biological mechanisms for localized prostate cancer (PCa) outcomes remain mostly unknown. We aim to evaluate the role of serum immune-checkpoint-related (ICK) proteins and genetic variations in predicting outcomes of localized PCa. Methods We profiled the serum levels of 14 ICK-related proteins (BTLA, GITR, HVEM, IDO, LAG-3, PD-1, PD-L1, PD-L2, Tim-3, CD28, CD80, 4-1BB, CD27, and CTLA-4) in 190 patients with localized PCa. The genotypes of 97 single nucleotide polymorphisms (SNPs) from 19 ICK-related genes were analyzed in an extended population (N = 1762). Meta-data from ArrayExpress and TCGA was employed to validate and to probe functional data. Patients were enrolled and tumor aggressiveness, biochemical recurrence (BCR), and progression information were obtained. Statistical analyses were performed analyzing associations between serum biomarkers, genotypes, mRNA and outcomes. Results We showed that serum (s)BTLA and sTIM3 levels were associated with PCa aggressiveness (P
Data Loading...
